BioVeris Completes Merger With Roche
28-Jun-2007
BioVeris Corporation announced that on June 25, 2007 the Company's stockholders voted to approve Roche's acquisition of BioVeris, and that the transaction was completed.
The acquisition will allow Roche Diagnostics to expand its immunochemistry business from the human diagnostic field into new market segments such as life science research, life science development, patient self testing, veterinary testing, drug discovery, drug development and clinical trials. By acquiring BioVeris, Roche will own the complete patent estate of the electrochemiluminescence (ECL) technology deployed in its Elecsys product line which gives Roche Diagnostics the opportunity to fully exploit the entire immunochemistry market.
Other news from the department business & finance
